WinstonWınston
Back
Stock

Alexandria Real Estate Equities

ARE
35
REIT - Office · Real Estate
Also trades as: 0HCH.L GBP 0.43 (-0.90%)
Price
$43.02
-0.31 (-0.72%)
Market Cap
$7.50B
Exchange
New York Stock Exchange
Winston Score
35
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Oct 24, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
12/30
Growth
Weak
3/20
Cash Flow
Mixed
4/10
Stability
Mixed
3/10
Valuation
Data not available
0/10
Ownership
Good
10/15
Dividends
Good
3/5

35 of 100 counted points = Winston Score 35.

Track this stock — start free trial

Share count rising — dilution

+15.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 147.5M (2021) → 170.4M (2025)

§Winston Score History

The full picture

Alexandria Real Estate Equities owns and operates office and laboratory buildings that it rents to life science companies, biotech firms, and pharmaceutical companies. These specialized buildings are called "life science campuses" and are designed specifically for scientific research — they have extra ventilation, plumbing, and safety features that normal office buildings do not have. Alexandria is the largest owner of life science real estate in the United States, with major campuses in Boston, San Francisco, San Diego, and New York.

The company makes money by collecting rent from its tenants, which include many of the world's largest drug companies and hundreds of smaller biotech startups. As a Real Estate Investment Trust (REIT), it is required to pay out most of its income as dividends to shareholders. Alexandria's main competitive advantage is that life science lab space is expensive and difficult to build, making it hard for competitors to quickly replace what it offers. The biggest risk the company faces is a slowdown in biotech funding, which could reduce demand for new lab space and pressure occupancy rates.

Politician Trades

17 trades / 12mo

7 Congressional buys and 10 sells on ARE in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+8.0% YoY

YoY Growth Rate

Slow revenue growth

Reported EPS Growth

+109.4% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.64

30 Jun 2026: $0.06

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$0/ year

0.0% of revenue

Below sector average (1%)

Research and development spending

Insider Activity

11.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 years

$2.2B cash & investments

Quarterly Free Cash Flow

$2.2B cash & investments at current burn rate

Growth context

Alexandria Real Estate Equities is growing revenue at 8% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
74.0%
Premium pricing power — 74.0% gross margin
Profit after running costs
Operating Margin
3.1%
Thin — 3.1% operating margin
Return on the money invested
ROCE
-4.8%
Weak — -4.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-2.1%
Shrinking sales (-2.1% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
29.6%
Converts sales into free cash efficiently (29.6%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.82
Moderate — manageable debt (0.82)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
6.46%
Healthy income — 6.46% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record
Dividend Growth
-45.5%
Dividend cut (-45.5% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial